Your Immune System's Job Is Protecting You, Not Attacking You.

HLA-DQ2 is a cell-surface protein that presents antigens (foreign or self) to your T-cells, essentially showing your immune system what to attack and what to tolerate. This is one of the most important immune checkpoint genes in your body. When functioning normally, HLA-DQ2 presents self-antigens in a way that triggers immune tolerance; your T-cells learn not to attack your own tissues.

If you carry HLA-DQ2, roughly 25-30% of people with European ancestry do, your immune system is more likely to recognize certain self-antigens as foreign threats. HLA-DQ2 is nearly required for celiac disease susceptibility, but it’s also associated with increased risk for type 1 diabetes, lupus, and other autoimmune conditions. The variant doesn’t cause disease by itself; it creates the biological vulnerability.

This means your immune system has a built-in tendency to misclassify your own tissues. When you encounter a trigger (an infection, an injury, or in the case of celiac disease, gluten), your immune system mounts a response and sometimes fails to turn it off. You might develop digestive symptoms, joint pain, skin rashes, or systemic inflammation depending on which tissues your immune system targets.

CTLA4 is a checkpoint protein on the surface of T-cells that acts like a brake. When CTLA4 binds to signals from other immune cells, it tells T-cells to stop multiplying and stop attacking. This is essential for immune tolerance. Without a functioning CTLA4 brake, T-cells keep attacking long after the initial threat has been neutralized.

The CTLA4 +49A>G variant, carried by roughly 45% of the population, reduces CTLA4 expression or function slightly. This means your T-cells have a weaker brake pedal, making them more likely to remain active and continue attacking tissue even when the initial danger signal is gone. People with this variant have significantly higher risk of autoimmune disease, including type 1 diabetes, celiac disease, grave’s disease, and lupus.

You might experience persistent autoimmune symptoms because your T-cells simply don’t turn off efficiently. Your immune system keeps attacking even after the trigger has been removed. You might get worse during stress (which amplifies T-cell activation) and better during periods of calm. You might find that treating infections aggressively (getting them resolved quickly) helps prevent autoimmune flares.

TNF (tumor necrosis factor-alpha) is one of the most powerful pro-inflammatory signaling molecules in your body. It’s produced by immune cells in response to infection, injury, or stress. In normal amounts, it tells your body to mount an immune response. But when TNF production is too high or doesn’t shut off quickly, it drives systemic inflammation and tissue damage.

The TNF -308G>A variant, present in roughly 30% of people with European ancestry, increases TNF-alpha production. People carrying the A allele produce more TNF-alpha in response to the same stimulus, meaning their inflammatory response is inherently more intense. This variant is associated with higher risk of rheumatoid arthritis, lupus, inflammatory bowel disease, and multiple sclerosis. Higher TNF levels also drive neuroinflammation, potentially contributing to brain fog and depression in autoimmune disease.

You might experience more severe inflammatory symptoms: joint pain, muscle aches, fatigue, or neurological symptoms like brain fog. Your inflammation might seem out of proportion to the trigger (a small infection causing weeks of fatigue, for example). You might find that anti-inflammatory interventions have a more dramatic effect on how you feel than they do for other people.

Interleukin-6 (IL-6) is a cytokine that signals your body to produce more immune cells and increases inflammation. Like TNF, it’s essential in small amounts but destructive when elevated chronically. IL-6 drives not only immune activation but also fever, fatigue, and neuroinflammation. People with high IL-6 often experience systemic symptoms that affect multiple tissues.

The IL6 -174G>C variant, carried by roughly 40% of the population, increases IL-6 production. People with the C allele have higher baseline IL-6 levels and mount a more intense IL-6 response to inflammation triggers. This variant is associated with increased risk of autoimmune disease, as well as depression, cognitive decline, and chronic fatigue. IL-6 is particularly involved in neuroinflammation, so elevated IL-6 can cause brain fog and mood changes.

You might experience whole-body inflammation: fatigue that doesn’t improve with sleep, generalized muscle or joint aches, brain fog, low mood, or fever-like symptoms even without active infection. Your symptoms might feel systemic rather than localized. You might notice your symptoms worsen dramatically during stress or infection, and take much longer to recover than expected.

PTPN22 is a protein that helps regulate T-cell signaling, particularly the development of regulatory T-cells (Tregs). Regulatory T-cells are your immune system’s peace-keepers; they actively suppress immune activation and maintain tolerance to self-antigens. PTPN22 is essential for this regulatory function. Without it, your Tregs don’t develop or function properly, and tolerance breaks down.

The PTPN22 R620W variant (rs2476601) increases autoimmune disease risk. This variant impairs PTPN22 function, meaning regulatory T-cells don’t develop normally and your immune system fails to maintain tolerance. People carrying this variant have significantly higher risk of type 1 diabetes, rheumatoid arthritis, lupus, and celiac disease. It’s one of the most reproducible autoimmune risk variants across multiple conditions.

You might experience progressive autoimmune symptoms that develop despite no obvious trigger. Your immune system gradually loses its ability to tolerate your own tissues. You might find that your symptoms develop slowly over months or years, or that they appear suddenly after a major infection or stressor that broke immune tolerance.

IRF5 (Interferon Regulatory Factor 5) is a transcription factor that controls type I interferon production. Type I interferons are cytokines your immune system produces in response to viral infection. They’re essential for fighting viruses, but when produced excessively, they drive autoimmune inflammation. IRF5 sits at a critical decision point: should your immune system mount a strong antiviral response, or should it stay calm?

IRF5 variants increase type I interferon production. People with IRF5 variants have an exaggerated interferon response, meaning their immune system mounts a more intense response to viral triggers and is more prone to interferon-driven autoimmune inflammation. IRF5 variants are associated with lupus, rheumatoid arthritis, and other autoimmune conditions. Elevated type I interferons are particularly characteristic of lupus and other systemic autoimmune diseases.

You might experience autoimmune flares triggered by viral infections. A cold or flu might trigger weeks or months of autoimmune symptoms. You might notice your autoimmune disease is worse during winter (when viral infections are more common) or during or shortly after acute illness. You might experience photosensitivity, malar rash, or joint pain that follows a viral illness pattern.